FDA Likely To Require Imaging Studies In Light Of TAVR Leaflet Findings
This article was originally published in The Gray Sheet
Computer tomography scans are likely to become a regular feature of transcatheter aortic valve replacement studies following findings of reduced leaflet mobility with current TAVR and surgical valve devices.
You may also be interested in...
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.